Intrathecal baclofen in current neuromodulatory practice: established indications and emerging applications.
Intrathecal baclofen (ITB) has evolved into a standard treatment for severe spasticity of both spinal and cerebral origin. The accumulated promising data from reported series of patients receiving ITB therapy together with the fact that spastic hypertonia commonly coexists with other neurological disorders have constituted a solid basis for offering this kind of treatment to patients suffering from other movement disorders. These include motor disorders such as dystonia, amyotrophic lateral sclerosis, status dystonicus, Hallervorden-Spatz disease, Freidreich's ataxia, "stiff-man" syndrome, but also vegetative states after revere brain trauma, anoxic encephalopathy or other pathology and more recently, various chronic pain syndromes. In this article, on the basis of the established applications of ITB therapy, we review the important emerging indications of this rewarding neuromodulation method and attempt to identify its future potential beneficial role in other chronic and otherwise refractory neurological disorders.
Panourias
I G
IG
P S. Kokkalis Hellenic Center for Neurosurgical Research, Athens, Greece.
Themistocleous
M
M
Sakas
D E
DE
D001418:Baclofen / Q000627:therapeutic use*; D004599:Electric Stimulation Therapy; D004567:Electrodes, Implanted; D006801:Humans; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D009422:Nervous System Diseases / Q000150:complications; D013116:Spinal Cord / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects
D009125:Muscle Relaxants, Central; D001418:Baclofen